Literature DB >> 20943724

Industry sponsored bias in cost effectiveness analyses.

Ava John-Baptiste, Chaim Bell.   

Abstract

Mesh：

Year:  2010        PMID： 20943724     DOI： 10.1136/bmj.c5350

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  8 in total

1.  A glimpse into the black box of cost-effectiveness analyses.

Authors:  Ava A John-Baptiste; Chaim Bell
Journal:  CMAJ       Date:  2011-03-14       Impact factor: 8.262

2.  Timely and complete publication of economic evaluations alongside randomized controlled trials.

Authors:  Joanna C Thorn; Sian M Noble; William Hollingworth
Journal:  Pharmacoeconomics       Date:  2013-01       Impact factor: 4.981

Review 3.  A Review of Phosphate Binders in Chronic Kidney Disease: Incremental Progress or Just Higher Costs?

Authors:  Wendy L St. Peter; Lori D Wazny; Eric Weinhandl; Katie E Cardone; Joanna Q Hudson
Journal:  Drugs       Date:  2017-07       Impact factor: 9.546

Review 4.  Economic Evaluations in National Cancer Institute-Sponsored Network Cancer Clinical Trials.

Authors:  Van T Nghiem; Riha Vaidya; Gary H Lyman; Dawn L Hershman; Scott D Ramsey; Joseph M Unger
Journal:  Value Health       Date:  2020-10-09       Impact factor: 5.725

5.  Cost-effectiveness of phosphate binders among patients with chronic kidney disease not yet on dialysis: a long way to go.

Authors:  Rana Rizk
Journal:  BMC Nephrol       Date:  2016-07-08       Impact factor: 2.388

6.  Characteristics of Cost-effectiveness Studies for Oncology Drugs Approved in the United States From 2015-2020.

Authors:  Alyson Haslam; Mark P Lythgoe; Emma Greenstreet Akman; Vinay Prasad
Journal:  JAMA Netw Open       Date:  2021-11-01

Review 7.  A systematic review and methodological evaluation of published cost-effectiveness analyses of aromatase inhibitors versus tamoxifen in early stage breast cancer.

Authors:  Ava A John-Baptiste; Wei Wu; Paula Rochon; Geoffrey M Anderson; Chaim M Bell
Journal:  PLoS One       Date:  2013-05-06       Impact factor: 3.240

8.  Prevention of Surgical Site Infections: A Systematic Review of Cost Analyses in the Use of Prophylactic Antibiotics.

Authors:  Abdul K R Purba; Didik Setiawan; Erik Bathoorn; Maarten J Postma; Jan-Willem H Dik; Alex W Friedrich
Journal:  Front Pharmacol       Date:  2018-07-18       Impact factor: 5.810
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.